News

Aerobic exercise triggers a surge of dopamine in the brain that can significantly improve movement and coordination during the aging process, a new study in mice suggests. By providing “neurochemical evidence” for the benefits of staying active, researchers found that regular physical activity can help offset the natural decline of…

GT-02287, an oral therapy being developed by Gain Therapeutics, can increase glucocerebrosidase (GCase) enzyme activity in the brains of people with Parkinson’s disease. Results from a Phase 1b trial (NCT06732180) show that approximately three months of treatment with GT-02287 was safe and led to a robust reduction…

The Michael J. Fox Foundation (MJFF) has awarded a $1 million research grant to MODAG to advance new PET imaging tools aimed at detecting Parkinson’s disease earlier and more accurately. Specifically, the funding will support the clinical development of MODAG-009, a PET tracer designed to measure…

Stress may be linked to higher levels of inflammation in people with Parkinson’s disease, according to a new analysis of data collected during the COVID-19 pandemic. The findings were reported in the study, “The interplay between stress, inflammation and Parkinson’s disease: insights from the COVID-19 pandemic,”…

Biotechnology company Ophidion is teaming up with Neuronasal, a clinical-stage company focused on nose-to-brain delivery of therapies for central nervous system disorders, to develop ways to deliver treatments for Parkinson’s disease and other conditions to the brain using noninvasive technology. The companies said…

Kenai Therapeutics said the first patient has been dosed in a Phase 1 clinical trial testing the safety and efficacy of RNDP-001, its experimental cell replacement therapy for Parkinson’s disease. The REPLACE trial (NCT07106021) is recruiting up to 12 people with moderate to severe idiopathic (of unknown cause)…

Three research teams investigating five high-potential targets for new Parkinson’s disease therapies received initial funding under a multi-year initiative from the Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grants are the first to be awarded under MJFF’s Targets to Therapies Initiative, which aims to advance the…

ACI-7104, an experimental vaccine being tested in people with early-stage Parkinson’s disease, has been generally well tolerated and is showing early signals that it may slow disease progression, according to interim Phase 2 data from its developer, AC Immune. “The interim Phase 2 data shows the…

Solengepras, an experimental once-daily pill for Parkinson’s disease, significantly reduces the time patients spend with re-emerging symptoms, known as off episodes. New Phase 2 data suggest the treatment reduces both the frequency and length of these difficult periods when standard medication wears off. The trial (…

Dysfunctional nerve cells in the brain’s motor command center may be driving the rigid brain wave patterns associated with Parkinson’s disease, a new supercomputer simulation reveals. The study suggests that specific neurons, known as PT5B, significantly alter brain wave frequency during movement. These neurons are responsible for…